WE-E-BRE-07: High-Throughput Mapping of Proton Biologic Effect

Authors


Abstract

Purpose:

To systematically relate the relative biological effectives (RBE) of proton therapy to beam linear energy transfer (LET) and dose.

Methods:

Using a custom irradiation apparatus previously characterized by our group, H460 NSCLCs were irradiated using a clinical 80MeV spot scanning proton beam. Utilizing this system allowed for high-throughput clonogenic assays performed in 96-well tissue culture plates as opposed to the traditional 6-well technique. Each column in the 96-well plate received a set LET-dose combination. By altering the total number of dose repaintings, numerous dose-LET configurations were examined to effectively generate surviving fraction (SF) data over the entire Bragg peak. The clonogenic assay was performed post-irradiation using an INCell Analyzer for colony quantification. SF data were fit to the linear-quadratic model for analysis.

Results:

Irradiation with increasing LETs resulted in decreased cell survival largely independent of dose. A significant correlation between LET and SF was identified by two-way ANOVA and the extra sum-of-squares F test. This trend was obscured at the lower LET values in the plateau region of the Bragg peak; however, it was clear for LET values at and beyond the Bragg peak. Data fits revealed the SF at a dose of 2Gy (SF2) to be 0.48 for the lowest tested LET (1.55keV/um), 0.47 at the end of the plateau region (4.74keV/um) and 0.33 for protons at the Bragg peak (10.35keV/um). Beyond the Bragg peak we measured SF2s of 0.16 for 15.01keV/um, 0.02 for 16.79keV/um, and 0.004 for 18.06keV/um.

Conclusion:

We have shown that our methodology enables high-content automated screening for proton irradiations over a range of LETs. The observed decrease in cellular SF in high LET regions confirms an increased RBE of the radiation and suggests further evaluation of proton RBE values is necessary to optimize clinical outcomes.

Rosalie B. Hite Graduate Fellowship in Cancer Research, NIH Program Project Grant P01CA021239

Ancillary